» Articles » PMID: 23576486

Approval Summary: Cetuximab in Combination with Cisplatin or Carboplatin and 5-fluorouracil for the First-line Treatment of Patients with Recurrent Locoregional or Metastatic Squamous Cell Head and Neck Cancer

Overview
Journal Oncologist
Specialty Oncology
Date 2013 Apr 12
PMID 23576486
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

On November 7, 2011, the U.S. Food and Drug Administration approved cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer. Approval was based on a randomized study of 442 patients conducted outside the U.S. Cisplatin (100 mg/m2 intravenously) or carboplatin (area under the curve 5 intravenously) on day 1 with 5-fluorouracil (1,000 mg/m2/day continuous intravenous infusion days 1-4) were administered every 3 weeks. Cetuximab, 400 mg/m2 intravenously, was administered initially followed by cetuximab, 250 mg/m2 intravenously weekly. After completion of six planned treatment courses, cetuximab patients without progression continued cetuximab 250 mg/m2 weekly. The study used European Union (EU)-approved cetuximab rather than U.S.-approved cetuximab. U.S.-approved cetuximab provides approximately 28% higher exposure relative to EU-approved cetuximab in a pharmacokinetic comparability study in monkeys. Overall survival, the primary efficacy endpoint, was significantly improved in cetuximab-treated patients (hazard ratio [HR]: 0.80; 95% confidence interval [CI]: 0.64-0.98; p = .034, stratified log-rank test). Median survival times were 10.1 and 7.4 months, respectively. Progression-free survival (PFS) was also significantly improved in patients receiving cetuximab (HR: 0.57; 95% CI: 0.46-0.72; p < .0001). Median PFS times were 5.5 and 3.3 months, respectively. Response rates were 35.6% and 19.5% (odds ratio: 2.33; 95% CI: 1.50-3.60; p = .0001). Adverse reactions (≥25%) from cetuximab plus chemotherapy treatment included nausea, anemia, vomiting, neutropenia, rash, asthenia, diarrhea, and anorexia. Conjunctivitis occurred in 10% of cetuximab patients. Other adverse reactions, sometimes severe, included infusion reactions, hypomagnesemia, hypocalcemia, and hypokalemia.

Citing Articles

Monoclonal antibody biosimilars for cancer treatment.

Broer L, Knapen D, de Groot D, Mol P, Kosterink J, de Vries E iScience. 2024; 27(6):110115.

PMID: 38974466 PMC: 11225859. DOI: 10.1016/j.isci.2024.110115.


Electrochemical Sensing Device for Carboplatin Monitoring in Proof-of-Concept Drug Delivery Nanosystems.

Pusta A, Tertis M, Ardusadan C, Mirel S, Cristea C Nanomaterials (Basel). 2024; 14(9).

PMID: 38727386 PMC: 11085464. DOI: 10.3390/nano14090793.


Innovations in Molecular Biomarkers and Biomaterial-Based Immunotherapies for Head & Neck Cancer.

Wong S, Manon V, Young S, Viet C Curr Surg Rep. 2024; 12(4):45-51.

PMID: 38523630 PMC: 10954983. DOI: 10.1007/s40137-024-00386-z.


Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy.

Fantini M, Arlen P, Tsang K Front Immunol. 2023; 14:1275904.

PMID: 38077389 PMC: 10704476. DOI: 10.3389/fimmu.2023.1275904.


The genes regulating sensitivity of tumor cells to T cell-mediated killing: could they be potential personalized immunotherapeutic targets in head and neck squamous cell carcinoma?.

Hu S, Duan H, Lu Y, Huang S Discov Oncol. 2023; 14(1):199.

PMID: 37926766 PMC: 10625926. DOI: 10.1007/s12672-023-00806-z.


References
1.
Bonner J, Harari P, Giralt J, Cohen R, Jones C, Sur R . Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2009; 11(1):21-8. DOI: 10.1016/S1470-2045(09)70311-0. View

2.
Frampton J . Cetuximab: a review of its use in squamous cell carcinoma of the head and neck. Drugs. 2010; 70(15):1987-2010. DOI: 10.2165/11205010-000000000-00000. View

3.
Mesia R, Rivera F, Kawecki A, Rottey S, Hitt R, Kienzer H . Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol. 2010; 21(10):1967-1973. PMC: 2946862. DOI: 10.1093/annonc/mdq077. View

4.
Salomon D, Brandt R, Ciardiello F, Normanno N . Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995; 19(3):183-232. DOI: 10.1016/1040-8428(94)00144-i. View

5.
Baselga J, Trigo J, Bourhis J, Tortochaux J, Cortes-Funes H, Hitt R . Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head.... J Clin Oncol. 2005; 23(24):5568-77. DOI: 10.1200/JCO.2005.07.119. View